Publications, Clinical Trial Results, Pending Approvals, and Milestone Payments - Research Report on Merck, Johnson & Johnson,

    Publications, Clinical Trial Results, Pending Approvals, and Milestone
Payments - Research Report on Merck, Johnson & Johnson, Allergan, Amarin, and
                                     Isis

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 23, 2013

NEW YORK, October 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Merck &
Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Allergan, Inc. (NYSE:
AGN), Amarin Corporation plc (NASDAQ: AMRN), and Isis Pharmaceuticals, Inc.
(NASDAQ: ISIS). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Merck & Co., Inc. Research Report

On October 14, 2013, Merck & Co., Inc. (Merck) and Endocyte, Inc. (Endocyte)
announced the online publication of results from the randomized Phase II
PRECEDENT trial for vintafolide in the Journal of Clinical Oncology (JCO), the
official journal of the American Society of Oncology. The results from the
Phase II PRECENDENT trial, as reported in JCO online, showed that
administration of vintafolide plus pegylated liposomal doxorubicin (PLD)
versus PLD alone in women with platinum-resistant ovarian cancer resulted in a
median progression-free survival (PFS) of 5.0 months compared to 2.7 months
for those treated with PLD alone. "Targeting the folate receptor, which is
expressed on the majority of epithelial ovarian cancers, is a potentially
promising strategy, especially when combined with a companion diagnostic that
is designed to identify patients who are most likely to respond to the
treatment, a hallmark of personalized medicine," said R. Wendel Naumann, M.D.,
Associate Director of Gynecologic Oncology at Carolina HealthCare System's
Levine Cancer Institute, Charlotte, N.C. The Full Research Report on Merck &
Co., Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/430d_MRK]

--

Johnson & Johnson Research Report

On October 17, 2013, Johnson & Johnson announced that its Board of Directors
has declared a Q4 2013 cash dividend of $0.66 per share on the Company's
common stock. According to the Company, the dividend is payable on December
10, 2013, to shareholders of record at the close of business on November 26,
2013, with an ex-dividend date of November 22, 2013. The Full Research Report
on Johnson & Johnson - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

--

Allergan, Inc. Research Report

On October 7, 2013, Allergan, Inc. (Allergan) announced that the results from
a non-randomized, case-controlled study recently published in the PLOS ONE
scientific online journal suggests cost recovery and long-term savings for
morbidly obese patients undergoing Laparoscopic Adjustable Gastric Banding
(LAGB or banding) and Laparoscopic Roux-enY Gastric Bypass (LRYGB or bypass)
procedures. "This analysis continues to support existing evidence that
bariatric surgery - especially gastric banding - can cut healthcare spending
on obesity and related co-morbidities quite significantly for patients, payers
and the overall healthcare system," said John Dixon, MBBS, PhD, FRACGP, FRCP
Edin, Baker IDI Heart and Diabetes Institute, Melbourne, Australia. "This data
proves that there is a cost benefit to including bariatric surgery as a core
component of health insurance plans and providing easier access to patients."
The Full Research Report on Allergan, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/182a_AGN]

--

Amarin Corporation plc Research Report

On October 16, 2013, Amarin Corporation plc (Amarin) announced that the FDA
Endocrinologic and Metabolic Drugs Advisory Committee has voted 9 to 2 against
approval of Vascepa capsules for use as an adjunct to diet and exercise and in
combination with a statin in the treatment of adult patients with high
triglycerides with mixed dyslipidemia and coronary heart disease (CHD) or a
CHD risk equivalent. The Company informed that the FDA intends to make its
decision regarding the approval of the ANCHOR Supplemental New Drug
Application (sNDA) on December 20, 2013, Prescription Drug User Fee Act
(PDUFA) goal date for the sNDA. The Full Research Report on Amarin Corporation
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/7cf9_AMRN]

--

Isis Pharmaceuticals, Inc. Research Report

On October 16, 2013, Isis Pharmaceuticals, Inc. (Isis) announced that it has
earned a $10 million milestone payment from Biogen Idec, in relation to the
selection and advancement of ISIS-DMPK[RX] to treat myotonic dystrophy type I
(DM1). "In less than two years, we discovered and advanced ISIS-DMPK[Rx] into
development, and we plan to begin human clinical studies next year," said B.
Lynne Parshall, COO at Isis. "In our preclinical studies, we and our
collaborators, Drs. Charles Thornton and Thurman Wheeler at the University of
Rochester, have been able to target the toxic RNA with antisense, remove the
toxic RNA and restore normal cell function. We look forward to working with
Biogen Idec to move this program into human clinical trials," added C. Frank
Bennett, Ph.D., Senior Vice President of Research at Isis. The Full Research
Report on Isis Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/fcfc_ISIS]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)